Evidence map›Paper›PMID 42550681›Full record

ArticleFuture oncology (London, England)2026

Smoldering multiple myeloma: a multi-country mixed-methods study on disease perceptions and patient treatment preferences.

Matthew Quaife, Cecilia Jimenez-Moreno, Blanca Gros Otero, Aisha Asra, Niodita Gupta-Werner, Katharine S Gries, Marie-Kristin Leisten, Kathryn Matt, Robin Carson, Robyn Dennis and 3 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Matthew QuaifePatient Centred Research, Evidera, London, UK.
Cecilia Jimenez-MorenoPatient Centred Research, Evidera, London, UK.
Blanca Gros OteroJohnson & Johnson, Madrid, Spain.
Aisha AsraJohnson & Johnson, London, UK.
Niodita Gupta-WernerJohnson & Johnson, Horsham, PA, USA.
Katharine S GriesJohnson & Johnson, Raritan, NJ, USA.
Marie-Kristin LeistenJohnson & Johnson, Neuss, Germany.
Kathryn MattJohnson & Johnson, Raritan, NJ, USA.
Robin CarsonJohnson & Johnson, Spring House, PA, USA.
Robyn DennisJohnson & Johnson, Raritan, NJ, USA.
Jianming HeJohnson & Johnson, Raritan, NJ, USA.
Bennett LevitanJohnson & Johnson, Titusville, NJ, USA.
Sacheeta BathijaJohnson & Johnson, Raritan, NJ, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTo understand disease perceptions and treatment preferences of patients with high-risk smoldering multiple myeloma (HR-SMM) or multiple myeloma (MM) that recently progressed from HR-SMM, and to estimate the minimum progression-free survival (min-PFS) required to accept the treatment burden.

methodsThis mixed-methods study interviewed 50 patients (HR-SMM and MM 1:1) from the USA, France, Italy, and Spain. Qualitative semi-structured interviews explored symptoms, quality of life, and awareness and expectations of SMM treatments. A quantitative thresholding exercise elicited the min-PFS for patients to accept a hypothetical treatment. Results were reported for HR-SMM and MM.

resultsThe most common symptoms were fatigue (68%) and pain (56%); 20% were asymptomatic. Most treatment-naïve patients (

conclusionsConsiderable psychological, physical, and functional burdens were imposed on HR-SMM patients by potential disease progression. Most patients were willing to receive treatment to delay progression and reduce symptomatic burden.

Indexed as

Multiple MyelomaPatient PreferenceSmoldering Multiple MyelomaAdultAgedAged, 80 and overDisease ProgressionFemaleHumansMaleMiddle AgedProgression-Free SurvivalQuality of LifeSymptom BurdenHigh-risk smoldering multiple myelomaimpact on lifeminimum acceptable progression-free survivalpatient preferencetreatment expectation

Identifiers

PMID42550681
PMCPMC13540126

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.